<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859521</url>
  </required_header>
  <id_info>
    <org_study_id>20-116-SA</org_study_id>
    <nct_id>NCT00859521</nct_id>
  </id_info>
  <brief_title>Levetiracetam 1000 mg Under Fasting Conditions</brief_title>
  <official_title>A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Levetiracetam 1000 mg Tablet Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      THe objective of this study is to compare the rate and extent of absorption of an&#xD;
      investigational formulation of levetiracetam 1000 mg tablet to an equivalent oral dose of the&#xD;
      commercially available reference product under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Concentration</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
    <description>Bioequivalence based on Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
    <description>Bioequivalence based on AUC0-inf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
    <description>Bioequivalence based on AUC0-t</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Keppra®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>1000 mg Tablet</description>
    <arm_group_label>Levetiracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keppra®</intervention_name>
    <description>1000 mg Tablet</description>
    <arm_group_label>Keppra®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        All subjects must satisfy the following criteria to be considered for study participation:&#xD;
&#xD;
          -  Subject must be male or non-pregnant, non-breast-feeding female&#xD;
&#xD;
          -  Subject must be at least 18 years of age&#xD;
&#xD;
          -  Subject must have a Body Mass Index (BMI) between 19 and 30 kg/m2, inclusive, and body&#xD;
             weight should be at least 50 kg (110 lbs)&#xD;
&#xD;
          -  Female Subjects - not surgically sterile or at least two years postmenopausal - must&#xD;
             agree to utilize one of the following forms of contraception, if sexually active with&#xD;
             a male partner, from screening through completion of the study. Approved forms of&#xD;
             contraception are abstinence, double barrier (condom with spermicide, diaphragm with&#xD;
             spermicide), intra-uterine device (IUD), or vasectomized partner (6 months minimum&#xD;
             since vasectomy).&#xD;
&#xD;
          -  Subject must voluntarily consent to participate in this study and provide their&#xD;
             written informed consent prior to the start of any study-specific procedures.&#xD;
&#xD;
          -  Subject is willing and able to remain in the study unit for the entire duration of&#xD;
             each confinement period and return for any outpatient visits.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects may be excluded for any of the following:&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurologic, oncologic, or psychiatric disease or any other condition which, in the&#xD;
             opinion of the Investigator would jeopardize the safety of the subject or the validity&#xD;
             of the study results.&#xD;
&#xD;
          -  Has a clinically significant abnormal finding on the physical exam, medical history,&#xD;
             ECG or clinical laboratory results at screening.&#xD;
&#xD;
          -  History or presence of allergic or adverse response to levetiracetam or related drugs.&#xD;
&#xD;
          -  Has been on a significantly abnormal diet during the four weeks preceding the first&#xD;
             dose of study medication.&#xD;
&#xD;
          -  Has donated blood or plasma within 30 days prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Has participated in another clinical trial within 30 days prior to the first dose of&#xD;
             study medication.&#xD;
&#xD;
          -  Has used any over-the-counter (OTC) medication, including nutritional supplements,&#xD;
             within 7 days prior to the first dose of study medication.&#xD;
&#xD;
          -  Has used any prescription medication, including hormonal contraceptive or hormonal&#xD;
             replacement therapy, within 14 days prior to the first dose of study medication.&#xD;
&#xD;
          -  Has been treated with any known enzyme altering drugs such as barbiturates,&#xD;
             phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first&#xD;
             dose of study medication.&#xD;
&#xD;
          -  Has smoked or used tobacco products within 90 days prior to the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Subject has consumed alcohol, caffeine/xanthine, or grapefruit containing beverages&#xD;
             and foods from 48 hours prior to the dose of study medication and throughout the&#xD;
             sample collection period.&#xD;
&#xD;
          -  Is a female with a positive pregnancy test result.&#xD;
&#xD;
          -  Female who has used implanted or injected hormonal contraceptives anytime during the 6&#xD;
             months prior to study start.&#xD;
&#xD;
          -  Has an intolerance to venipuncture.&#xD;
&#xD;
          -  Has a positive urine screen for drugs of abuse (amphetamines, barbiturates,&#xD;
             benzodiazepines, cocaine, cannabinoids, opiates)&#xD;
&#xD;
          -  Has a history of drug or alcohol abuse.&#xD;
&#xD;
          -  Has had a positive test for, or has been treated for hepatitis B, hepatitis C or HIV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James P Doherty, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDRA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CEDRA Clinical Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>March 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <results_first_submitted>July 9, 2009</results_first_submitted>
  <results_first_submitted_qc>July 9, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2009</results_first_posted>
  <last_update_submitted>July 9, 2009</last_update_submitted>
  <last_update_submitted_qc>July 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Levetiracetam (Test) First</title>
          <description>Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Keppra® (Reference) First</title>
          <description>Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levetiracetam (Test) First</title>
          <description>Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Keppra® (Reference) First</title>
          <description>Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Concentration</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 1000 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Keppra®</title>
            <description>Keppra® 1000 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Concentration</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.281" spread="7.756"/>
                    <measurement group_id="O2" value="31.512" spread="8.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>96.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.4</ci_lower_limit>
            <ci_upper_limit>101</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</title>
        <description>Bioequivalence based on AUC0-inf</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 1000 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Keppra®</title>
            <description>Keppra® 1000 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</title>
          <description>Bioequivalence based on AUC0-inf</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>mcg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.155" spread="49.732"/>
                    <measurement group_id="O2" value="285.645" spread="50.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>98.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.9</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</title>
        <description>Bioequivalence based on AUC0-t</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 1000 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Keppra®</title>
            <description>Keppra® 1000 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</title>
          <description>Bioequivalence based on AUC0-t</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>mcg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.172" spread="47.012"/>
                    <measurement group_id="O2" value="272.498" spread="48.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.</non_inferiority_desc>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>98.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>97.2</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

